(June 9, 2009 - Insidermedicine) Targeting lipoprotein(a) may be an effective means of lowering the risk of myocardial infarction, according to a study published in the Journal of the American Medical Association.
Here are the LDL-cholesterol treatment targets from the third report of the National Cholesterol Education Program (NCEP):
• High risk: <100 mg/dL (optional goal: <70 mg/dL)
• Moderately high & moderate risk: <130 mg/dL
• Lower risk: <160 mg/dL
Researchers from Copenhagen University Hospital used data from 40,486 white individuals to analyze the link between plasma lipoprotein(a) levels, lipoprotein(a) kringle IV type 2 (KIV-2) size polymorphism genotype, and myocardial infarction.
In all three studies, decreasing numbers of lipoprotein(a) KIV-2 repeats were linked with increasing plasma levels of lipoprotein(a), and both were linked with an increasing risk for MI.
We had a chance to speak with Dr. Borge Nordestgaard, one of the authors of this study, who offered some further insight.
Today's research suggests that lipoprotein(a) may be a suitable target for the prevention of MI, although randomized trials are needed for confirmation.
For Insidermedicine in Depth, I'm Dr. Susan Sharma.